Kyverna says miv-cel CAR-T drives ACR70 response in Phase 1 trial in refractory ACPA-positive rheumatoid arthritis

Kyverna

Kyverna

KYTX

0.00
  • Kyverna highlighted updated Phase 1 COMPARE trial results for miv-cel in ACPA-positive, treatment-refractory rheumatoid arthritis, presented at EULAR 2026.
  • Patients showed broad clinical improvement following a single infusion, supporting potential for meaningful disease control in a hard-to-treat population.
  • Findings also pointed to durable suppression of disease-related immune activity while preserving protective vaccine immunity, consistent with an immune “reset” effect.
  • Safety remained consistent with prior experience, with no severe cytokine release syndrome or neurotoxicity reported in the Phase 1 cohort.
  • The randomized Phase 2 portion comparing miv-cel with rituximab has started and is fully enrolled, setting up a key read-through for differentiation.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyverna Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606030800PRIMZONEFULLFEED9731008) on June 03, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.